KERX Key Stats
- Notable Analyst Rating Changes 06/19: (CX) (ADBE) (LINE) Upgraded; (CLF) (S) (BB... Jun 19
- StreetInsider.com Pre-Open Movers 6/19: (PLX) (CYTK) (ADBE) Higher; (OSH) (VNDA)... Jun 19
- JPMorgan Starts Keryx Biopharmaceuticals (KERX) at Overweight Street Insider Jun 19
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way fo... Jun 17
- KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principa... Jun 13
- Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You) Jun 11
- Biotech Stock Mailbag: 2013 Clinical Trials Calendar Jun 7
- Solid Showing At WCN Conference For Keryx: Catalysts Still To Come Jun 4
- KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principa... Jun 4
- Clovis Among Top Small-Cap Biotech Picks By Legendary Fund Managers In Q1/2013 Jun 4
KERX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Keryx Biopharmaceuticals is up 373.6% over the last year vs S&P 500 Total Return up 23.89%, ACADIA Pharmaceuticals up 1082%, and Supernus Pharmaceuticals up 30.74%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for KERX
Pro Report PDF for KERX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download KERX Pro Report PDF
Pro Strategies Featuring KERX
Did Keryx Biopharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.